GlassScriptPhysician profile
Jennifer Bienz
NPI 1306295936
$991.61
in general payments reported to CMS, 2019-2025
18 companies · $65.20 in 2025
The $65.20 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $69.22 · 2024: $857 · 2025: $65.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Neurelis, INC. | $124.80 | 2024 | Valtoco |
| Astellas Pharma US INC | $89.45 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $84.86 | 2024 | Farxiga, Airsupra, Lokelma |
| Acadia Pharmaceuticals INC | $83.15 | 2024 | Nuplazid |
| Abbvie INC. | $83.07 | 2024-2025 | |
| Novo Nordisk INC | $76.51 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $46.31 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $45.28 | 2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $45.12 | 2023-2024 | |
| Antares Pharma, INC. | $36.19 | 2024 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $32.91 | 2024 | |
| Ucb, INC. | $27.39 | 2024 | Nayzilam |
| Merck Sharp & Dohme LLC | $22.16 | 2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.25 | 2024 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.73 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $15.05 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bienz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.